Registry following people with head and neck squamous cell carcinoma
Collects data on real-world treatment and outcomes in adults with head and neck cancer.
Plain-language title generated from the registry record
Registry title: Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Key facts
- Where
- Essen and Hanover, GermanySee the 2 sites
Where in Germany
- Universitätsklinikum EssenEssen, GermanyNot yet recruiting
- Onkologie/Studienzentrum am Raschplatz GbRHanover, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AIO-Studien-gGmbH
- Trial code
- NCT06380686
- Record updated
- 6 November 2026
- Original description
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.Read full original descriptionShow less
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Inclusion: Age ≥ 18 years; Able to understand and willing to sign written informed consent; Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx); Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care; Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease.